10x Genomics
322 hedge funds and large institutions have $2.02B invested in 10x Genomics in 2025 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 107 increasing their positions, 98 reducing their positions, and 57 closing their positions.
119% more call options, than puts
Call options by funds: $5.72M | Put options by funds: $2.61M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
40% more capital invested
Capital invested by funds: $1.44B → $2.02B (+$578M)
12% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 57
2% more funds holding
Funds holding: 317 → 322 (+5)
9% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 98
1.31% less ownership
Funds ownership: 107.43% → 106.12% (-1.3%)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$52.3M |
| 2 |
CC
Casdin Capital
New York
|
+$21.1M |
| 3 |
QCM
Quantinno Capital Management
New York
|
+$17.7M |
| 4 |
FCM
Freshford Capital Management
Rye Brook,
New York
|
+$12.6M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$11.8M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$63.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$42.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$23.8M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$20M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$8.43M |
TXG Hedge Fund Activity: Q4 2025 in Review
322 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2025, worth a combined $2.02B — up 40% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new TXG positions and 57 closed out — a net gain of 7 holders — while 107 added to existing stakes and 98 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $52.3M. The largest seller was Millennium Management, cutting an estimated $63.4M.
- 322 institutional investors held 10x Genomics (TXG) as of Q4 2025, up from 317 in Q3 2025.
- Funds reported $2.02B of 10x Genomics stock for Q4 2025, up 40% quarter-over-quarter.
- 64 funds opened new 10x Genomics positions in Q4 2025 and 57 closed out, a net change of +7 holders.
- The largest 10x Genomics buyer in Q4 2025 was Fidelity Investments, an estimated $52.3M added.
- The largest 10x Genomics seller in Q4 2025 was Millennium Management, an estimated $63.4M sold.
Based on aggregated 13F filings for Q4 2025.